Access to New Drug Policy Sharing Forum


13:30 PM-15:20 PM 第一阶段 Phase I
13:30 PM-14:00 PM 第一阶段 Phase I
  • 主题报告1
  • Keynote Speech 1
  • 中国新,全球新——机遇与挑战
  • The Opportunities and Challenges in Drug Innovation: First in Class or First in China
  • 李靖,药渡经纬信息科技(北京)有限公司董事长、联合创始人
  • Jin LI,Founder and Chair of Pharmacodia
14:00 PM-14:30 PM
  • 主题报告2
  • Keynote Speech 2
  • 以临床价值为导向的抗肿瘤药物临床研发及审评报告
  • Clinical Value-oriented Anti-tumor Drug Clinical Research and Development and Review Report
  • 杨志敏,国家药品监督管理局药品审评中心化药临床一部部长
  • YANG Zhimin, Leader of the Medical Review Department I, Centre for Drug Evaluation (CDE), China National Medical Products Administration (NMPA)
15:20 PM-17:00 PM 第二阶段 Phase II
15:20 PM-15:50 PM
  • 主题报告1
  • Keynote Speech 1
  • 创新药物临床价值体现的重要性
  • The Importance of the Clinical Calue Demonstration for Innovative Drugs
  • 宣建伟,中山大学药学院医药经济研究所所长
  • XUAN Jianwei,Director of Health Economics Research Institute, Sun Yat-sen University
15:50 PM-16:10 PM
  • 主题报告2
  • Keynote Speech 2
  • 商业健康保险与医药创新融合发展的思考
  • Commercial Health Insurance and Access of Innovative Medicine
  • 韩世明,波士顿咨询合伙人
  • Samuel HAN,Partner of Boston Consulting Group
16:10 PM-17:00 PM
  • 主题讨论
  • Panel
  • 满足临床需求,回归临床价值
  • Satisfy Clinical Needs and Return to Clinical Value
  • Moderator
  • 俞卫,上海创奇健康发展研究院执行院长
  • YU Wei,Executive Director,China Healthcare Innovation Platform Academy
  • Panelists
  • 宣建伟, 中山大学药学院医药经济研究所所长
  • 翟青, 复旦大学附属上海肿瘤医院药剂科主任
  • 李怡平,药明巨诺联合创始人、董事长兼首席执行官
  • 韩世明,波士顿咨询合伙人
  • XUAN Jianwei, Director of Health Economics Research Institute, Sun Yat-sen University
  • DI Qing, Director of Pharmacy, Fudan University Affiliated Oncology Hospital
  • James LI, Co-Founder, Chairman and Chief Executive Officer, JW Therapeutics
  • Samuel HAN, Partner of Boston Consulting Group
Specification:
  • Released: September 17, 2020
  • Last update: September 19, 2020
  • Version: 1.1